Allergan Plc (AGN) 226.82 $AGN
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 226.82 (-6.69), PFE: 34.15 (-0.44), TEVA: 50.14 (-1.23), AMPH: 15.64 (-0.51)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 226.82 (-6.69), PFE: 34.15 (-0.44), ANAC: 99.06 (-0.14)
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board
BusinessWire - Thu Jun 23, 6:00AM CDT
--- Carol Gallagher, NEA Partner and Current Board Member, Named Chair -
AGN: 226.82 (-6.69)
Global Migraine Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Allergan, Biofrontera, Mallinckrodt - Research and Markets
BusinessWire - Wed Jun 22, 1:12PM CDT
Research and Markets has announced the addition of the "Migraine - Pipeline Review, H1 2016" report to their offering.
AGN: 226.82 (-6.69)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 29.33 (-1.00), AGN: 226.82 (-6.69), TEVA: 50.14 (-1.23), AMPH: 15.64 (-0.51)
Asian shares mostly up as investors await more Brexit polls
By TERESA CEROJANO - AP - Tue Jun 21, 10:52PM CDT
MANILA, Philippines (AP) — Asian shares were mostly higher Wednesday, with investors focused on Thursday's vote on Britain's possible withdrawal from the European Union and after relief over U.S. Federal Reserve Chair Janet Yellen's statement that the Fed would remain cautious in raising interest rates.
AGN: 226.82 (-6.69), T: 41.73 (-0.15), OSIS: 55.07 (-0.88), VZ: 54.71 (+0.04), UAL: 41.31 (-3.86)
United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 226.82 (-6.69), IPXL: 29.33 (-1.00), CP.TO: 161.15 (-4.96), WERN: 22.13 (-0.27), CP: 124.14 (-6.08), ASEI: 37.29 (+0.33), IMPV: 44.01 (-2.29), UAL: 41.31 (-3.86)
Allergan Falls 1.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:01PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $230.20 to a high of $238.26. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $234.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 226.82 (-6.69)
Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"
and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million.
IPXL: 29.33 (-1.00), AGN: 226.82 (-6.69)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 226.82 (-6.69), RARE: 49.40 (-2.55)
Research and Markets - Global Generic Drugs Market 2016 - Forecasts to 2020 with Teva, Sandoz, Allergan, Mylan, Sun Pharma & STADA Arzneimittel Dominating
PR Newswire Europe - Fri Jun 17, 10:10AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
AGN: 226.82 (-6.69)
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 226.82 (-6.69), PFE: 34.15 (-0.44), PRTK: 12.92 (-0.50)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.15 (unch), AGN: 226.82 (-6.69), HZNP: 16.20 (-1.24), MYL: 43.82 (-2.34)
Follow Icahn Into Allergan Stock
Jack Foley - Amigobulls - Fri Jun 17, 5:08AM CDT
The biotech sector will recover its gains that it has lost since July 2015. Fundamentally strong Allergan will benefit handsomely.
AGN: 226.82 (-6.69), VRX: 20.35 (-1.90)
Allergan Glaucoma Gel Stent Filing Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:19PM CDT
Allergan plc's (AGN) Premarket Notification Application for the XEN Glaucoma Treatment System has been accepted by the FDA for review.
AGN: 226.82 (-6.69), BMY: 70.94 (-1.70), TLGT: 6.76 (+0.12), AMPH: 15.64 (-0.51)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 226.82 (-6.69), BIIB: 230.56 (-8.06), MDT: 83.70 (-2.07), ALXN: 113.87 (-9.70), XOM: 89.90 (-1.90), BMY: 70.94 (-1.70), CVX: 102.39 (-2.05)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 226.82 (-6.69), SGNT: 15.05 (-0.27), TEVA: 50.14 (-1.23)
Former SkinMedica President Ted Schwarz named to NuGene Board of Directors
GlobeNewswire - Wed Jun 15, 7:00AM CDT
NuGene (OTCBB:NUGN) today announced that it has appointed Ted Schwarz to their Board of Directors effective June 13, 2016. Mr. Schwarz previously served as President of SkinMedica, a leading topical medical aesthetics company. During his nine years at SkinMedica he directed the commercial, new product and R&D teams allowing for seven straight years of market leading growth positioning SkinMedica for its successful acquisition by pharmaceutical giant Allergan for $350MM.
AGN: 226.82 (-6.69)
Allergan Announces FDA Acceptance of the 510(k) Premarket Notification Filing for the XEN Glaucoma Treatment System
PR Newswire - Wed Jun 15, 6:31AM CDT
Allergan plc (NYSE: AGN) announced today that the 510(k) Premarket Notification Application for the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) has been accepted for filing by the U.S. Food and Drug Administration (FDA). XEN45 is a minimally invasive implantable crosslinked gelatin shunt used to reduce intraocular pressure (IOP) associated with refractory glaucoma.
AGN: 226.82 (-6.69)
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 226.82 (-6.69), PFE: 34.15 (-0.44), TEVA: 50.14 (-1.23), AMPH: 15.64 (-0.51)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 226.82 (-6.69), PFE: 34.15 (-0.44), ANAC: 99.06 (-0.14)
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board
BusinessWire - Thu Jun 23, 6:00AM CDT
--- Carol Gallagher, NEA Partner and Current Board Member, Named Chair -
AGN: 226.82 (-6.69)
Global Migraine Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Allergan, Biofrontera, Mallinckrodt - Research and Markets
BusinessWire - Wed Jun 22, 1:12PM CDT
Research and Markets has announced the addition of the "Migraine - Pipeline Review, H1 2016" report to their offering.
AGN: 226.82 (-6.69)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 29.33 (-1.00), AGN: 226.82 (-6.69), TEVA: 50.14 (-1.23), AMPH: 15.64 (-0.51)
Asian shares mostly up as investors await more Brexit polls
By TERESA CEROJANO - AP - Tue Jun 21, 10:52PM CDT
MANILA, Philippines (AP) — Asian shares were mostly higher Wednesday, with investors focused on Thursday's vote on Britain's possible withdrawal from the European Union and after relief over U.S. Federal Reserve Chair Janet Yellen's statement that the Fed would remain cautious in raising interest rates.
AGN: 226.82 (-6.69), T: 41.73 (-0.15), OSIS: 55.07 (-0.88), VZ: 54.71 (+0.04), UAL: 41.31 (-3.86)
United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 226.82 (-6.69), IPXL: 29.33 (-1.00), CP.TO: 161.15 (-4.96), WERN: 22.13 (-0.27), CP: 124.14 (-6.08), ASEI: 37.29 (+0.33), IMPV: 44.01 (-2.29), UAL: 41.31 (-3.86)
Allergan Falls 1.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:01PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $230.20 to a high of $238.26. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $234.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 226.82 (-6.69)
Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"
and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million. IPXL: 29.33 (-1.00), AGN: 226.82 (-6.69)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 226.82 (-6.69), RARE: 49.40 (-2.55)
Research and Markets - Global Generic Drugs Market 2016 - Forecasts to 2020 with Teva, Sandoz, Allergan, Mylan, Sun Pharma & STADA Arzneimittel Dominating
PR Newswire Europe - Fri Jun 17, 10:10AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
AGN: 226.82 (-6.69)
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 226.82 (-6.69), PFE: 34.15 (-0.44), PRTK: 12.92 (-0.50)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.15 (unch), AGN: 226.82 (-6.69), HZNP: 16.20 (-1.24), MYL: 43.82 (-2.34)
Follow Icahn Into Allergan Stock
Jack Foley - Amigobulls - Fri Jun 17, 5:08AM CDT
The biotech sector will recover its gains that it has lost since July 2015. Fundamentally strong Allergan will benefit handsomely.
AGN: 226.82 (-6.69), VRX: 20.35 (-1.90)
Allergan Glaucoma Gel Stent Filing Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:19PM CDT
Allergan plc's (AGN) Premarket Notification Application for the XEN Glaucoma Treatment System has been accepted by the FDA for review.
AGN: 226.82 (-6.69), BMY: 70.94 (-1.70), TLGT: 6.76 (+0.12), AMPH: 15.64 (-0.51)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 226.82 (-6.69), BIIB: 230.56 (-8.06), MDT: 83.70 (-2.07), ALXN: 113.87 (-9.70), XOM: 89.90 (-1.90), BMY: 70.94 (-1.70), CVX: 102.39 (-2.05)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 226.82 (-6.69), SGNT: 15.05 (-0.27), TEVA: 50.14 (-1.23)
Former SkinMedica President Ted Schwarz named to NuGene Board of Directors
GlobeNewswire - Wed Jun 15, 7:00AM CDT
NuGene (OTCBB:NUGN) today announced that it has appointed Ted Schwarz to their Board of Directors effective June 13, 2016. Mr. Schwarz previously served as President of SkinMedica, a leading topical medical aesthetics company. During his nine years at SkinMedica he directed the commercial, new product and R&D teams allowing for seven straight years of market leading growth positioning SkinMedica for its successful acquisition by pharmaceutical giant Allergan for $350MM.
AGN: 226.82 (-6.69)
Allergan Announces FDA Acceptance of the 510(k) Premarket Notification Filing for the XEN Glaucoma Treatment System
PR Newswire - Wed Jun 15, 6:31AM CDT
Allergan plc (NYSE: AGN) announced today that the 510(k) Premarket Notification Application for the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) has been accepted for filing by the U.S. Food and Drug Administration (FDA). XEN45 is a minimally invasive implantable crosslinked gelatin shunt used to reduce intraocular pressure (IOP) associated with refractory glaucoma.
AGN: 226.82 (-6.69)
